Lipocine (LPCN) Interest & Investment Income (2015 - 2025)
Lipocine's (LPCN) quarterly Interest & Investment Income came in at $174208.0 in Q3 2025, down 36.32% YoY from $273574.0 in Q3 2024, and down 12.3% on a QoQ basis from $198637.0 in Q2 2025.
Lipocine (LPCN) Interest & Investment Income (2015 - 2025) Analysis & Trends
Lipocine (LPCN) has 11 years of Interest & Investment Income data on file, last reported at $174208.0 in Q3 2025.
- Quarterly Interest & Investment Income fell 36.32% year-over-year to $174208.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $831474.0 (down 31.46% YoY) and the FY2024 annual result came in at $1.1 million, down 16.1% from the prior year.
- Interest & Investment Income slipped to $174208.0 in Q3 2025, from $198637.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $379521.0 in Q2 2023 to a low of -$49400.0 in Q1 2022.
- A 5-year average of $191227.2 and a median of $225511.0 in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2021 — Interest & Investment Income sank 137.47% — and 2022, when it surged 1224.06%.
- Tracing LPCN's Interest & Investment Income over 5 years: stood at $22443.0 in 2021, then surged by 1224.06% to $297158.0 in 2022, then gained by 0.75% to $299379.0 in 2023, then declined by 22.13% to $233118.0 in 2024, then fell by 25.27% to $174208.0 in 2025.
- The last three Interest & Investment Income figures came in at $174208.0 (Q3 2025), $198637.0 (Q2 2025), and $225511.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 174,208.00 |
| Jun 30, 2025 | 198,637.00 |
| Mar 31, 2025 | 225,511.00 |
| Dec 31, 2024 | 233,118.00 |
| Sep 30, 2024 | 273,574.00 |
| Jun 30, 2024 | 308,845.00 |
| Mar 31, 2024 | 331,364.00 |
| Dec 31, 2023 | 299,379.00 |
| Sep 30, 2023 | 317,569.00 |
| Jun 30, 2023 | 379,521.00 |
| Mar 31, 2023 | 370,469.00 |
| Dec 31, 2022 | 297,158.00 |
| Sep 30, 2022 | 163,966.00 |
| Jun 30, 2022 | 69,877.00 |
| Mar 31, 2022 | -49,400.00 |
| Dec 31, 2021 | 22,443.00 |
| Sep 30, 2021 | 17,264.00 |
| Jun 30, 2021 | 22,273.00 |
| Mar 31, 2021 | -22,459.00 |
| Dec 31, 2020 | 2,921.00 |